Earnings calls

Metropolis Healt concall ledger

Every earnings call for METROPOLIS — management tone, guidance, KPIs and promise tracking, quarter by quarter.

METROPOLIS · 5 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 05 Feb 2026Call held 05 Feb 2026

METROPOLIS Q3 FY26 Earnings Call Transcript & Analysis

Group Revenue Growth—+26% YoYGroup 9-Month Revenue Growth—+24% YoYGroup Patient Volume Growth—+14% YoYGroup Test Volume Growth—+13% YoYGroup EBITDA Margin23.4%

Group revenues grew 26% YoY, reaching 3.5 million patient volumes and 7.3 million test volumes.

Read full transcript & analysis

Q2 FY26Published 06 Nov 2025Call held 06 Nov 2025

METROPOLIS Q2 FY26 Earnings Call Transcript & Analysis

Group Revenue—+23% YoYOrganic Revenue—+12% YoYOrganic EBITDA Margin26.8%Group EBITDA Margin25.4%Group PAT₹52.9 cr

Organic EBITDA Margin 26.8%. Group revenue grew 23% YoY in Q2 FY26.

Read full transcript & analysis

Q1 FY26Published 14 Aug 2025Call held 14 Aug 2025

METROPOLIS Q1 FY26 Earnings Call Transcript & Analysis

Group Revenue—+23% YoYOrganic Revenue—+13% YoYOrganic EBITDA₹87.5 cr+12% YoYOrganic EBITDA Margin24.7%Group EBITDA Margin23.1%

Organic EBITDA ₹88 cr (+12% YoY). Group revenue grew 23.2% YoY, driven by strong organic growth and recent acquisitions.

Read full transcript & analysis

Q4 FY25Published 14 May 2025Call held 14 May 2025

METROPOLIS Q4 FY25 Earnings Call Transcript & Analysis

Revenue—+12% YoYAdjusted EBITDA₹325 cr+14% YoYAdjusted EBITDA Margin24.4%

Adjusted EBITDA (FY25) ₹325 cr (+14% YoY); Adjusted EBITDA Margin (FY25) 24.4%. FY25 Revenue grew 12% YoY.

Read full transcript & analysis

Q3 FY25Published 05 Feb 2025Call held 05 Feb 2025

METROPOLIS Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹323 cr+11% YoYEBITDA₹71.6 cr+9% YoYEBITDA Margin22.2%PAT₹31.5 cr+15% YoYPAT Margin9.8%

Revenue (Q3 FY25) ₹323 cr (+11% YoY); EBITDA (Q3 FY25) ₹72 cr (+9% YoY); EBITDA Margin (Q3 FY25) 22.2%. Q3 FY25 Revenue of ₹323 crores, up 10.9% YoY.

Read full transcript & analysis